Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Effect of Liraglutide on Macrophage Polarization in Human Adipose Tissue and Peripheral Blood
The objective of this study is to test the hypothesis that liraglutide (commonly known as Victoza) can promote an anti-inflammatory macrophage phenotype in human adipose tissue and blood, thereby reducing localized and systemic inflammation which are risk factors for cardiovascular disease and may contribute to hyperglycemia. This will be done after 4 weeks of treatment during which weight will remain stable, and again after 12 weeks, during which liraglutide-related weight loss occurs.
It has now been established that the high risk of cardiovascular disease that is associated
with obesity and type 2 diabetes is related to the systemic inflammation that underlies these
conditions. Previous studies have shown that there are numerous types of immune cells in
human adipose tissue, some of these are the macrophages. These cells can exist in two states:
M2, which can inhibit classical inflammatory response, and M1 which secrete proinflammatory
cytokines. The investigators have data to suggest that the role of inflammatory cells in
adipose tissue is a strong contributor to systemic inflammation. A recent study showed that a
GLP-1 analog (liraglutide, also known as Victoza) may help decrease inflammation via
promoting M2 differentiation of macrophages. The purpose of this study is to quantify
macrophage phenotype (M1 vs M2) in subcutaneous adipose tissue in moderately-obese diet
controlled diabetics at baseline, after four weeks of weight-maintenance using liraglutide,
and after 12 weeks of liraglutide treatment as compared to placebo.
Aim 1: Quantify M1 and M2 (surface and intracellular markers) polarization via flow cytometry
in subcutaneous abdominal adipose tissue and peripheral blood mononuclear cells at baseline
and after 4 weeks administration of liraglutide versus placebo to weight-stable, obese, type
2 diabetic patients. Weight loss will be prevented in order to ascertain the effect of
liraglutide alone.
Aim 2: Quantify M1 and M2 (surface and intracellular markers) polarization via flow cytometry
in subcutaneous adipose tissue and peripheral blood mononuclear cells after 12 weeks of
liraglutide treatment, during which dietary restrictions are lifted and spontaneous weight
loss, as would occur in the clinical setting, is allowed. To eliminate confounding by weight
loss, a placebo-treated group will undergo matched dietary weight loss for comparison to the
liraglutide group to ascertain whether changes in macrophage polarization at 12 weeks are
greater in the liraglutide group.
Aim 3: Quantify macrophage-mediated localized and systemic inflammation by measuring
M1/M2-related inflammatory cytokines in adipose tissue and peripheral blood after 4 and 12
weeks administration of liraglutide versus placebo to obese, type 2 diabetic patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |